Biotechnology company Compass Pathways plc (NASDAQ: CMPS) and Greenbrook TMS Inc (NASDAQ: GBNH) have entered into a three-year research collaboration agreement to explore delivery models for investigational COMP360 psilocybin treatment. The parties will research and investigate models for the delivery of scalable, commercial COMP360 within healthcare systems, assuming FDA approval. The initial phase will involve research into the delivery of COMP360 at treatment centers across the U.S. that are working with people suffering with treatment-resistant depression (TRD) and other mental health cond…
